[ET Net News Agency, 21 September 2021] HUTCHMED (China) Limited (00013) announced that
it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of
surufatinib (SULANDA in China) in combination with toripalimab compared with FOLFIRI to
treat patients with advanced neuroendocrine carcinoma (NEC) who have progression of
disease or intolerable toxicity after previous first-line chemotherapy.
The study is a randomized, controlled, open-label, multi-centre study where
approximately 200 patients are expected to be enrolled. (RC)